Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEW 11/9 SEDAR filing:
"The requirement to file this report was triggered on October 16, 2018 when Armistice, on behalf of certain investment funds managed by it, participated in an underwritten public offering of the Issuer (the “Public Offering”) and acquired 6M pre-funded Common Share purchase warrants with no expiry date (the “Pre-Funded Warrants”), each exercisable for one Common Share at an exercise price of US$0.01 per share and 6M Common Share purchase warrants (the “October 16th Warrants”), each exercisable for one Common Share at an exercise price of US$0.75 per share until October 16, 2023.
Since the date of the Public Offering, Armistice, on behalf of certain investment funds managed by it, has exercised 1.2M of the Pre-Funded Warrants and continued to trade in Common Shares of the Issuer on the NASDAQ market."
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00029068
Shares have closed below $1.00 since October 11th.
30 trading days ~ business days will be 11/21 included.
Thursday 11/22 Thanksgiving = market closed.
Black Friday 11/23: early close.
IF any delisting note : AFTER Monday,November 26th.
Armistice/Boyd transaction was 10/11.
Tu 10/9.....Vol 103.6K.....open/close 1.37-1.33....low/high 1.30-1.44
We 10/10.........1.7M .....................1.32-1.04 .................0.99-1.85
Th 10/11......... 4.2M ..................... 1.11-0.81 ................ 0.80-1.50
Fr 10/12.......... 3.3M .................... 0.68-0.64 ................ 0.62-0.68
Mo 10/15 .......351.5K ...................0.65-0.64 ................ 0.63-0.65
Gap down 10/11-10/12 ... $0.68- $0.80
New 10/18/18 filing:
(10/11 Event)
Amount beneficially owned:
Armistice Capital, LLC – 565,800
Armistice Capital Master Fund Ltd. – 565,800
Steven Boyd – 565,800
Percent of class:
Armistice Capital, LLC – 9.99%
Armistice Capital Master Fund Ltd. – 9.99%
Steven Boyd – 9.99%
There is a 10/17 filing:
....On October 16, 2018 the Company completed an underwritten public offering in the US....resulting in the sale of 2,775,231 common shares, pre-funded warrants exercisable for 16,563,335 common shares, at an exercise price of US$0.01/sh, and warrants exercisable for 20M common shares, at an exercise price of US$0.75/sh. The Company received gross proceeds of approximately US$14.3M, prior to deducting discount/commissions/expenses.
As of the date of this report, the Company believes that it has regained compliance with Nasdaq’s stockholders’ equity requirement....the Company believes its stockholders’ equity is in excess of US$2.5M.
...The Company is awaiting confirmation from Nasdaq that it has achieved compliance with the US$2.5M stockholders’ equity requirement and intends to make a further announcement upon receiving such notice of compliance.
Last 10/16 filling page 33:
"To the Company’s knowledge, Armistice Capital Master Fund, Ltd. and/or its affiliates (collectively “Armistice”), currently a holder of in excess of 10% of the Company’s outstanding Common Shares, participated in (i) a registered direct offering in October 2017, pursuant to a placement agent agreement dated October 10, 2017 between the Company and H.C. Wainwright, and (ii) the registered direct offerings completed in March 2018, pursuant to placement agent agreements dated March 12, 2018 and March 18, 2018 between the Company and H.C. Wainwright; and Armistice is participating in the October 2018 Offering."
CPRX: swing trade. PDUFA 11/28.
A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication. While all medications have labeling that informs health care stakeholders about medication risks, only a few medications require a REMS.
https://www.fda.gov/Drugs/DrugSafety/REMS/default.htm
Many FDA approvals yesterday 9/18. Mostly REMS and labeling but MANY. Maybe IPCI is next.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
1/10 starts tomorrow 9/14
"If they resign current position, it will take this up."
That's 100% right. Unfortunately Odidi's ego won't let that happen.
10 business days fabius. r/s should start by/before Friday 9/14. Most probably to be announced only the night before.
By September 7th, 2018 Andrew Patient's first year accomplishments:
70% share price down
IPCI's lowest price in history
3+ direct offerings
1/10 or 1/15 Reverse Split
I believe there're more but those are the "greatest"
1/5 to 1/15.
I guess 1/10 it is.
Anybody going to the shareholders meeting tomorrow?
Beachguy3363,..Don't you think a take over could be positive?...at these levels...maybe?
I agree with you about Boyd as one catalyst. Check his record with CERECOR:
4/28 $5M Private placement with Armistice Capital
5/15 Boyd and Greenleaf to Board of Directors
8/14 CERC-501 rights SOLD for $25M
If we expect the same outcome for IPCI, then a new offering won't be in place.
I'm also keep thinking about Shawn Graham, a "lobbyist".
Why is he proposed as a director? Will he help with Health Canada? China? perhaps EMA?
Unfortunately we'll be the last ones to know about it.
You have to vote and don't leave in blank.
You haven't noticed but this is written in the proxy:
"I (Tilator) authorize you to act in accordance with my instructions set out above. I hereby revoke any proxy previously given with respect to the Meeting.
If no voting instructions are indicated above, this Proxy will be voted FOR a matter by the persons named above..."
To leave in blank means a vote in favor.
If you don't vote your vote won't be count and we need "Majority Vote"
VOTE "WITHHOLD" if you're against the Directors and all proposals.
NEW "Proposed Director Shawn Graham" was with Odidi on the China-Pharma-Smarta-Shanghai inauguration.
"Mr. Graham is the President and CEO of G&R Holdings Inc., which assists companies with developing and implementing global projects and business alliance strategies with a special focus on globalizing with China. Mr. Graham previously served as 31st Premier of Province of New Brunswick (from Oct 2006 to Oct 2010). He is a former Chair of the Council of The Federation, Co-chair of Northeastern Governors and Eastern Canadian Premiers, and Co-chair of a Pan-Canadian trade mission to China. He is currently a
member of the advisory board of the faculty of business, University of New Brunswick, Saint John as well as a national board member to Ducks Unlimited Canada. Mr.Graham has been awarded an Honorary Doctor of Laws Degree from the University of New Brunswick."
"...We are continuing our efforts to identify opportunities internationally, particularly in China, that could if effectuated provide product distribution alternatives through partnerships and therefore would not likely require an investment or asset acquisition by us. We recently visited China where discussions toward establishing a partnership to facilitate future development activities are ongoing. We have not at this time entered into and may not ever enter into any such arrangements..."
Right, those $#s are as of 2/28/18. Armistice and Frigate/Anson loaded in March and Proxy vote doesn't show any change in management. Those companies might know something we don't.
Research and Development
Expenditures for R&D for the three months ended 2/28/18 were higher by $232,936 compared to the three months ended 2/28/17. The increase is primarily due to expenses related to costs of clinical studies and other third party costs related to advancing our Oxycodone ER product candidate and ANDA product candidates.
Revenue: 2/28/18 = $334,518 compared to 2/28/17 = $1,235,366
Expenses.................3,425,780 ...................................... 3,084,278
Net loss from operations (3,091,262).............................(1,848,912)
Net loss per common share
Basic and diluted............. (0.09) ..................................... (0.07)
Cash 2/28/18 = $270,226 ........................... 11/30/17 = $1,897,061
Total assets ....5,392,181 .............................................. 7,396,781
Convertible debenture 1,306,436 .................................. 1,290,465
Total liabilities............. ............8,116,133 .......................7,010,398
Shareholders' (deficiency...)/equity (2,723,952)................ 386,383
Total liabilities and shareholders' equity 5,392,1815 ....... 7,396,781
Vote "WITHHOLD"
1. Election of Directors:
Dr. Isa Odidi
Dr. Amina Odidi
Bahadur Madhani
Shawn Graham
Kenneth Keirstead
Eldon Smith
2. Appointment of Auditors:
Reappointment of MNP LLP, Chartered Professional Accountants as
Auditors and to authorize the Directors to fix the auditors’ remuneration
3. Stock Option Plan Resolution:
The resolution approving all unallocated options, rights and entitlements under the Company’sstock option plan as more particularly described in the management proxy circular for the Meeting
4. Stock Option Extension Resolution:
The resolution approving the two-year extension of the performance-based options granted to certain directors and officers described in the management proxy circular for the Meeting
CLEAN THE SWAMP !
Meeting/voting points:
1. to receive the audited consolidated financial statements of the Company for the financial year ended November 30, 2017, and the
auditor’s report thereon;
2. to elect six (6) directors;
3. to reappoint the auditor and to authorize the directors to fix the auditor’s remuneration;
4. to pass a resolution to approve all unallocated options, rights and entitlements under the Company’s stock option plan;
5. to approve the two year extension of the performance-based stock options granted to certain directors and officers as more
particularly described in the management information circular prepared for the Meeting (the “Management Proxy Circular”); and
6. to transact such further and other business as may properly come before the Meeting or any adjournments thereof.
Last Filings with more than a hundred shares are below but we know Armistice has now 8.6M shares
2018-04-13 BANK OF MONTREAL /CAN/ ........... 31,263
2018-04-13 BANK OF MONTREAL /CAN/ ..... Put 30,500
2018-03-20 ARMISTICE CAPITAL, LLC .......... 8,227,500
2018-03-20 Frigate Ventures ............................ 2,916,666
2018-02-27 Blackstone Alternative Invest ................ 5,504
2018-02-15 Sabby Management ...................... 1,083,637
2018-02-14 MORGAN STANLEY .......................... 65,250
2018-02-14 SUSQUEHANNA INT.......................... 46,144
2018-02-14 Advisor Group, Inc.............................. 39,451
2018-02-14 UBS Group AG .................................... 8,622
2018-02-14 ROYAL BANK OF CANADA .............. 16,214
2018-02-14 DEUTSCHE BANK AG\ ....................... 6,812
2018-02-14 FIRST FOUNDATION ADVISORS ... 489,172
2018-02-13 GEODE CAPITAL MANAGEMENT.......13,756
2018-02-12 Financial Architects, Inc ......................... 2,000
2018-02-12 Argent Trust Co ................................... 59,693
2018-02-09 Tower Research Capital LLC (TRC)......... 500
2018-02-09 CITADEL ADVISORS LLC .......... Call 14,300
2018-02-09 CITADEL ADVISORS LLC .................. 11,262
2018-02-09 GROUP ONE TRADING, L.P. ............... 7,328
2018-02-08 TORONTO DOMINION BANK .................. 195
2018-02-07 Verity Asset Management, Inc............. 30,000
2018-02-05 THOMPSON DAVIS & CO., INC............ 2,500
SEDAR filing 3/29:
"...we wish to advise you of the following information in connection with its Annual and Special Meeting of Shareholders:
Date of meeting: May 15, 2018
Record date for notice: March 27, 2018
Record date for voting: March 27, 2018..."
NO PROXYvote yet, but we'll get it soon.
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00029068
The Markman Hearing is now reset for 6/22/2018, at 9:00 AM in Courtroom 6A before Judge Richard G. Andrews. Ordered by Judge Richard G. Andrews on 4/6/2018.
https://www.pacermonitor.com/public/case/21111005/Purdue_Pharma_LP_et_al_v_Intellipharmaceutics_International_Inc_et_al
Nothing yet. I believe we'll get it between April 11-17.
Email Proxyvote next week-before April 17.
Be sure to vote NO to everything, including Deloitte Firm.
IF Odidi steps out: IPCI share price goes %% up
BUT If Odidi is kicked out, IPCI shares will go %%%%%
Don't hesitate and send a vote of NO CONFIDENCE.
May 15th or April 18th?
SEDAR filling March 2nd
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00029068
Exemption Decisions (CBCA)
https://www1.ic.gc.ca/eic/site/cd-dgc.nsf/eng/cs07756.html
Thank you mopar44o!
Fiscal year 2017 results after market close on Thursday 2/15/18.
Conference call at 8 am (EST) on Friday 2/16/18.
The conference call will be conducted by Dr. Isa Odidi, Chairman, Chief Executive Officer, and Co-Chief Scientist and Andrew Patient, Chief Financial Officer.
Participants may access the call from North America by dialing toll-free 1-877-407-8033. International callers should dial (201) 689-8033. A webcast of the call will also be accessible at http://www.investorcalendar.com/event/25800
"I thought that South African company called Smart Pharmaceutical might be involved. It does look like the founder of the company, Ridwaan Enous, is in the photos at the far right. I am not sure if he is there as a friend or business partner."
I thought that too but there're only three flags on the ceremony/pictures: From Nigeria, China and Canada.
Smart Pharmaceuticals also has a logo and it's not on the screen/board.
Thank you Angelo, Great tip.
"wimusky...yes Oz county... I wish I could private message you.."
There are other ways. The easy ones: Stocktwits and Twitter.